EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In-cell cryo-electron tomography reveals differential effects of type I and type II kinase inhibitors on LRRK2 filament formation and microtubule association

Tamar Basiashvili iD, Joshua Hutchings iD, Siyu Chen iD, Eva P Karasmanis, William Alexander Flaherty iD, Andres E Leschziner iD, Elizabeth Villa iD

eLife · 2026

DOI: 10.7554/elife.111075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, 2026. Verfasst von Tamar Basiashvili und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, United States. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Microtubules, Protein Kinase Inhibitors. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Aligning Science Across Parkinson's, European Molecular Biology Organization, National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in leucine-rich repeat kinase 2 (LRRK2) are a leading contributor to developing familial and idiopathic Parkinson’s disease (PD). Most PD-causing LRRK2 mutations increase the kinase activity, leading to increased phosphorylation of Rab GTPases, disrupting vesicular trafficking, cytoskeletal dynamics, and autophagy. Under homeostatic conditions, the bulk of WT and PD-mutant LRRK2 is found in the cellular cytosol. However, exogenously expressed LRRK2 can form microtubule-associated filaments that have been shown to affect molecular transport along microtubules in vitro. While the physiological relevance of microtubule binding has not been established yet, inhibitors being designed and tested as therapeutics have been shown to either promote or prevent filament formation of LRRK2. In this study, we examine the localization and resulting molecular organization of hyperactive LRRK2-I2020T, a common PD mutant, in HEK 293FT cells treated with type I (MLi-2) or type II (GZD-824) kinase inhibitors. Treatment with a type I kinase inhibitor results in extensive LRRK2-I2020T decoration around microtubules and microtubule bundling. Stabilization of LRRK2-I2020T filaments by type I inhibitor treatment allowed us to build a full-length closed-kinase model of LRRK2-I2020T in its cellular environment. Conversely, treatment with a type II inhibitor resulted in minimal microtubule decoration by LRRK2-I2020T compared to type I inhibitor-treated cells. This study provides a structural framework for understanding how type I and type II kinase inhibitors differentially modulate LRRK2 filament formation, demonstrating that type I inhibitor treatment promotes a distinct filament architecture, whereas such assemblies are not observed with type II inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2MicrotubulesProtein Kinase InhibitorsHumansHEK293 CellsElectron Microscope TomographyCryoelectron MicroscopyParkinson DiseaseMutationIndazolesPyrimidines

Stichwörter der Autor:innen

LRRK2Parkinson's diseasecryo-EThumanmolecular biophysicsstructural biology

Substanzen

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanProtein Kinase Inhibitors2,6-dimethyl-4-(6-(5-(1-methylcyclopropoxy)-1H-indazol-3-yl)pyrimidin-4-yl)morpholineIndazolesPyrimidines

Autor:innen und Institutionen

  • Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, United States.
  • Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, United States.
  • Howard Hughes Medical Institute, Chevy Chase, United States.
  • Department of Molecular Biology, University of California San Diego, La Jolla, United States.
  • Department of Cellular and Molecular Medicine, School of Medicine, University of California San Diego, La Jolla, United States.

ORCID-Profile: Tamar Basiashvili, Joshua Hutchings, Siyu Chen, William Alexander Flaherty, Andres E Leschziner, Elizabeth Villa

Förderung

  • Aligning Science Across Parkinson's
  • European Molecular Biology Organization
  • National Science Foundation
  • American Heart Association
  • Jane Coffin Childs Memorial Fund for Medical Research
  • Howard Hughes Medical Institute
  • Michael J. Fox Foundation

Zitieren

APA

Basiashvili, T., Hutchings, J., Chen, S., Karasmanis, E. P., Flaherty, W. A., Leschziner, A. E., & Villa, E. (2026). In-cell cryo-electron tomography reveals differential effects of type I and type II kinase inhibitors on LRRK2 filament formation and microtubule association. eLife. https://doi.org/10.7554/elife.111075

Vancouver

Basiashvili T, Hutchings J, Chen S, Karasmanis EP, Flaherty WA, Leschziner AE, et al. In-cell cryo-electron tomography reveals differential effects of type I and type II kinase inhibitors on LRRK2 filament formation and microtubule association. eLife. 2026. doi:10.7554/elife.111075

BibTeX
@article{Basiashvili2026,
  author = {Basiashvili, Tamar and Hutchings, Joshua and Chen, Siyu and Karasmanis, Eva P and Flaherty, William Alexander and Leschziner, Andres E and Villa, Elizabeth},
  title = {In-cell cryo-electron tomography reveals differential effects of type I and type II kinase inhibitors on LRRK2 filament formation and microtubule association},
  journal = {eLife},
  year = {2026},
  doi = {10.7554/elife.111075}
}
Kostenlos starten →